carteolol has been researched along with Intraocular Pressure in 77 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Intraocular Pressure: The pressure of the fluids in the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the 24-h efficacy and safety of fixed combination carteolol/latanoprost (LCFC) and timolol/latanoprost (LTFC) in patients with primary open-angle glaucoma and ocular hypertension." | 9.41 | Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study. ( Aihara, M; Kishimoto, N; Kizaki, J; Saito, Y; Shibasaki, Y; Wada, Y, 2021) |
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 9.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To assess the intraocular pressure (IOP)-lowering effects and safety of a carteolol/latanoprost fixed combination drug (OPC-1085EL) vs latanoprost (Study 1) and carteolol (Study 2) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH)." | 9.22 | Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension. ( Ikegami, T; Ishikawa, Y; Kikuchi, S; Yamamoto, T, 2016) |
| "004% travoprost and 2% carteolol in patients with ocular hypertension (OHT) after laser peripheral iridotomy (LPI) or trabeculectomy in primary angle-closure glaucoma (PACG)." | 9.17 | [Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma]. ( Li, YX; Pang, YY; Yao, BQ, 2013) |
| "The effects of switching from topical beta-blockers (beta) to latanoprost (LA) on intraocular pressure (IOP) and IOP-reduction rate (IOP-RR) in patients with normal-tension glaucoma (NTG) were investigated." | 9.13 | Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma. ( Ikeda, Y; Ishibashi, T; Kinoshita, S; Mori, K; Nakajima, N; Naruse, S, 2008) |
| "To compare the ocular hypotensive activity and safety profile of long-acting 1% carteolol hydrochloride eye drops (long-acting formulation) to those of 1% carteolol hydrochloride eye drops(currently prescribed drug) for reduction of intraocular pressure." | 9.12 | [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product]. ( Yamamoto, T, 2007) |
| "Sublingual administration of carteolol or instillation into one eye reduces intraocular pressure (IOP) in both eyes." | 9.10 | Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity. ( Ishii, Y; Matsuki, S; Muraguchi, R; Nakagawa, M; Nakamura, K; Nakano, S; Nakatsuka, K; Uemura, N, 2002) |
| "3% metipranolol on intraocular pressure (IOP) in 45 patients with primary open-angle glaucoma (POAG) and ocular hypertension." | 9.09 | Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. ( Karaküçük, S; Mirza, GE; Temel, E, 2000) |
| "One hundred seventy-six patients with ocular hypertension or primary open-angle glaucoma were randomly assigned to receive either carteolol 1% twice a day or timolol maleate 0." | 9.08 | Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. ( Cohen, JS; Netland, PA; Nussbaum, LL; Stewart, WC; Weiss, H, 1997) |
| "No significant difference was found between carteolol 1% and 2%, when their effects on intraocular pressure were compared over a 4 week treatment period." | 9.06 | A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. ( Duff, GR, 1987) |
| "We performed a double-masked study in which 98 patients with ocular hypertension who had been previously treated with timolol received either timolol 0." | 9.06 | A double-masked comparison of carteolol and timolol in ocular hypertension. ( Krieglstein, GK; Mueller, B; Scoville, B; White, BG, 1988) |
| "In patients with normal-tension glaucoma (NTG), topical dorzolamide might enhance the vessel density (VD), topical carteolol decreased the VD in the inferior-temporal peripapillary retina, whereas topical brimonidine did not change the VD." | 8.02 | Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide. ( Chen, LC; Chuang, LH; Huang, SM; Lin, YH; Su, WW, 2021) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 7.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| "We prospectively investigated the efficacy and safety of switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) in patients with primary open-angle glaucoma or ocular hypertension." | 7.88 | Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. ( Inoue, K; Ishida, K; Iwasa, M; Shiokawa, M; Tomita, G, 2018) |
| "To evaluate the effects of carteolol hydrochloride (carteolol) on 24-h variations in intraocular pressure (IOP) in patients with normal-tension glaucoma (NTG)." | 7.76 | Effect of carteolol hydrochloride on 24-hour variation of intraocular pressure in normal-tension glaucoma. ( Nakamoto, K; Yasuda, N, 2010) |
| "A novel technique is described in which the effect of the beta-adrenoceptor antagonists timolol and carteolol, and the vasodilators sodium nitroprusside (SNP) and verapamil on intraocular pressure (IOP) and the distribution of ocular flow in the bovine arterially perfused eye is investigated using radiolabelled microspheres." | 7.69 | Drug effects on intraocular pressure and vascular flow in the bovine perfused eye using radiolabelled microspheres. ( Carr, RD; Humphries, RG; Millar, JC; Wilson, WS, 1995) |
| "Effects of the R(+)- and S(-)-isomers of befunolol and carteolol, beta-adrenoceptors with intrinsic sympathomimetic activity, on the rabbit intraocular pressure were tested." | 7.68 | Effects of the R(+)- and S(-)-isomers of beta-adrenoceptor blockers with intrinsic sympathomimetic activity, befunolol and carteolol, on rabbit intraocular pressure. ( Hagiwara, H; Hosokawa, T; Kasuya, Y; Koike, K; Takayanagi, I, 1991) |
| "The therapeutic effects of carteolol hydrochloride were evaluated in the treatment of 44 uveitis patients (51 eyes) with intraocular pressure elevation or secondary glaucoma." | 7.67 | Hypotensive effect of carteolol on intraocular pressure elevation and secondary glaucoma associated with endogenous uveitis. ( Ichiishi, A; Matsuda, H; Ohno, S, 1989) |
| "Carteolol is a nonselective beta-blocker with intrinsic sympathomimetic activity (I." | 6.67 | A long term clinical trial of carteolol in the management of glaucoma. Belgian Carteolol Study Participants. ( Goethals, M; Missotten, L; Vandeputte, O; Vercruysse, K, 1992) |
| "To evaluate the 24-h efficacy and safety of fixed combination carteolol/latanoprost (LCFC) and timolol/latanoprost (LTFC) in patients with primary open-angle glaucoma and ocular hypertension." | 5.41 | Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study. ( Aihara, M; Kishimoto, N; Kizaki, J; Saito, Y; Shibasaki, Y; Wada, Y, 2021) |
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 5.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To assess the intraocular pressure (IOP)-lowering effects and safety of a carteolol/latanoprost fixed combination drug (OPC-1085EL) vs latanoprost (Study 1) and carteolol (Study 2) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH)." | 5.22 | Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension. ( Ikegami, T; Ishikawa, Y; Kikuchi, S; Yamamoto, T, 2016) |
| "004% travoprost and 2% carteolol in patients with ocular hypertension (OHT) after laser peripheral iridotomy (LPI) or trabeculectomy in primary angle-closure glaucoma (PACG)." | 5.17 | [Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma]. ( Li, YX; Pang, YY; Yao, BQ, 2013) |
| "The effects of switching from topical beta-blockers (beta) to latanoprost (LA) on intraocular pressure (IOP) and IOP-reduction rate (IOP-RR) in patients with normal-tension glaucoma (NTG) were investigated." | 5.13 | Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma. ( Ikeda, Y; Ishibashi, T; Kinoshita, S; Mori, K; Nakajima, N; Naruse, S, 2008) |
| "To compare the ocular hypotensive activity and safety profile of long-acting 1% carteolol hydrochloride eye drops (long-acting formulation) to those of 1% carteolol hydrochloride eye drops(currently prescribed drug) for reduction of intraocular pressure." | 5.12 | [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product]. ( Yamamoto, T, 2007) |
| "To compare the additive effect of dorzolamide or carteolol to latanoprost on intraocular pressure (IOP) in glaucoma patients." | 5.12 | Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. ( Maruyama, K; Shirato, S, 2006) |
| "In this double-masked, randomised, intra-subject comparative study, 23 patients with bilateral primary open-angle glaucoma or bilateral ocular hypertension received sequentially, according to the randomised order of administration, each of the 2 following treatments: carteolol 2% LA once daily for 2 months and carteolol 2% regular twice daily for 2 months." | 5.11 | Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. ( Allaire, C; Cochereau, I; Elena, PP; Jaulerry, S; Kovalski, JL; Lablache Combier, M; Renard, P; Siou-Mermet, R; Williamson, W, 2005) |
| "These results suggest that topical carteolol hydrochloride may have a more favorable blood lipid profile than topical timolol maleate in postmenopausal black women with POAG or ocular hypertension." | 5.09 | Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women. ( Bartlett, JD; Olivier, M; Pensyl, D; Richardson, T; Whitaker, R; Wilson, MR, 1999) |
| "3% metipranolol on intraocular pressure (IOP) in 45 patients with primary open-angle glaucoma (POAG) and ocular hypertension." | 5.09 | Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. ( Karaküçük, S; Mirza, GE; Temel, E, 2000) |
| "Carteolol is a beta adrenoceptor antagonist used topically to reduce intraocular pressure, typically twice daily." | 5.09 | Ocular hypotensive efficacy and safety of once daily carteolol alginate. ( Allaire, C; Demailly, P; Trinquand, C, 2001) |
| "One hundred seventy-six patients with ocular hypertension or primary open-angle glaucoma were randomly assigned to receive either carteolol 1% twice a day or timolol maleate 0." | 5.08 | Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. ( Cohen, JS; Netland, PA; Nussbaum, LL; Stewart, WC; Weiss, H, 1997) |
| "5% levobunolol and 2% carteolol were compared in 59 patients with open-angle glaucoma or ocular hypertension." | 5.07 | A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol. ( Behrens-Baumann, W; Kimmich, F; Lue, J; Walt, JG, 1994) |
| " Its effect on intraocular pressure and heart rate was tested in a comparison with timolol maleate, as was subjective tolerance of it, in 28 eyes (14 subjects) with either ocular hypertension or simple chronic open-angle glaucoma." | 5.06 | [Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops]. ( Flury, H; Martenet, AC; Tournoux, A, 1986) |
| "We performed a double-masked study in which 98 patients with ocular hypertension who had been previously treated with timolol received either timolol 0." | 5.06 | A double-masked comparison of carteolol and timolol in ocular hypertension. ( Krieglstein, GK; Mueller, B; Scoville, B; White, BG, 1988) |
| "No significant difference was found between carteolol 1% and 2%, when their effects on intraocular pressure were compared over a 4 week treatment period." | 5.06 | A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. ( Duff, GR, 1987) |
| "To investigate the treatment persistence of carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution (CAR/LAT) and other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions (BB/FP) in the treatment of glaucoma." | 4.31 | Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions. ( Kashiwagi, K; Ouchi, K; Shibasaki, Y; Suginaka, M, 2023) |
| "In patients with normal-tension glaucoma (NTG), topical dorzolamide might enhance the vessel density (VD), topical carteolol decreased the VD in the inferior-temporal peripapillary retina, whereas topical brimonidine did not change the VD." | 4.02 | Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide. ( Chen, LC; Chuang, LH; Huang, SM; Lin, YH; Su, WW, 2021) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 3.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| ", tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells." | 3.91 | Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol. ( Akaishi, T; Fuwa, M; Kato, M; Mieda, M; Shimazaki, A; Taniguchi, T; Yamashita, N, 2019) |
| "We prospectively investigated the efficacy and safety of switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) in patients with primary open-angle glaucoma or ocular hypertension." | 3.88 | Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. ( Inoue, K; Ishida, K; Iwasa, M; Shiokawa, M; Tomita, G, 2018) |
| "To assess the potential of chitosan (CS) nanoparticles for ocular drug delivery by investigating their intraocular retention by γ-scintigraphy and intraocular pressure reduction." | 3.80 | Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits. ( Ali, A; Ali, J; Bhatnagar, A; Kumar, N, 2014) |
| "To evaluate the effects of carteolol hydrochloride (carteolol) on 24-h variations in intraocular pressure (IOP) in patients with normal-tension glaucoma (NTG)." | 3.76 | Effect of carteolol hydrochloride on 24-hour variation of intraocular pressure in normal-tension glaucoma. ( Nakamoto, K; Yasuda, N, 2010) |
| "In this study the acute effect of the topically-delivered non-selective beta-blockers timolol and carteolol, and the selective beta-blocker betaxolol, were evaluated with respect to ocular blood flow, intraocular pressure (IOP) and vessel resistance in rabbits' eyes." | 3.71 | Short-term effect of beta-adrenoreceptor blocking agents on ocular blood flow. ( Ishibashi, Y; Muto, T; Roy, S; Sato, T, 2001) |
| "Carteolol is a topical beta-blocker used in ophthalmology to decrease the intraocular pressure." | 3.70 | Vasorelaxing properties of carteolol in isolated porcine ciliary arteries. ( Champion, C; Flammer, J; Haefliger, IO; Kasper, J, 2000) |
| "A novel technique is described in which the effect of the beta-adrenoceptor antagonists timolol and carteolol, and the vasodilators sodium nitroprusside (SNP) and verapamil on intraocular pressure (IOP) and the distribution of ocular flow in the bovine arterially perfused eye is investigated using radiolabelled microspheres." | 3.69 | Drug effects on intraocular pressure and vascular flow in the bovine perfused eye using radiolabelled microspheres. ( Carr, RD; Humphries, RG; Millar, JC; Wilson, WS, 1995) |
| "Patients with primary open angle glaucoma and ocular hypertension were randomized to 62 patients of LA group (LA once a day) and 62 patients of CA group (CA twice a day) in this multicenter, open-label trial." | 2.75 | [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration]. ( Ishikawa, Y; Kawase, K; Matsuhisa, A; Migita, M; Muramatsu, T; Nakajima, T; Ono, J; Sugiura, T; Yamamoto, T, 2010) |
| "Carteolol treatment decreased high-density lipoprotein cholesterol levels by 3." | 2.67 | Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. ( Freedman, NJ; Freedman, SF; Keates, EU; Lobaugh, B; Ollie, A; Samsa, GP; Shields, MB, 1993) |
| "Carteolol is a nonselective beta-blocker with intrinsic sympathomimetic activity (I." | 2.67 | A long term clinical trial of carteolol in the management of glaucoma. Belgian Carteolol Study Participants. ( Goethals, M; Missotten, L; Vandeputte, O; Vercruysse, K, 1992) |
| "Intraocular pressure was measured for 3 days." | 2.67 | [The effect of carteolol. Prolonged and increased effect by liposome suspension]. ( Michaelis, L; Weber, U, 1992) |
| "Betaxolol was twice as effective at preventing the effect of IgG (34% to 37%) than that of zymosan (14%), regardless of the presence of BAK." | 1.32 | In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. ( Baudouin, C; Blondin, C; Cholley, B; Haeffner-Cavaillon, N; Hamard, P, 2003) |
| " The increased ocular bioavailability of 1% carteolol in the presence of alginic acid led to an equivalent concentration in the target tissue although administration was only once a day compared with twice a day for 1% carteolol alone." | 1.31 | A new long acting ophthalmic formulation of carteolol containing alginic acid. ( Driot, JY; Maurin, F; Sébastian, C; Séchoy, O; Tissié, G; Trinquand, C, 2000) |
| " This indicates that long-term use of topical carteolol increases peripheral blood flow in ONH tissue in the living rabbit eye." | 1.29 | [Effect of topical carteolol on tissue circulation in rabbit optic nerve head evaluated with the laser speckle microcirculation analyser]. ( Araie, M; Nagahara, M; Tamaki, Y; Tomidokoro, A; Tomita, K, 1995) |
| " The dosage forms were tested on intraocular hypertensive-induced rabbits." | 1.29 | Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. ( Hoffman, M; Maincent, P; Marchal-Heussler, L; Sirbat, D, 1993) |
| "8-OH carteolol was more effective in suppressing the water-load induced IOP rise in rabbits compared with carteolol on equimolar basis." | 1.28 | Ocular hypotensive effect of 8-hydroxycarteolol, a metabolite of carteolol. ( Enya, T; Kitazawa, Y; Sugiyama, K, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (25.97) | 18.7374 |
| 1990's | 25 (32.47) | 18.2507 |
| 2000's | 16 (20.78) | 29.6817 |
| 2010's | 11 (14.29) | 24.3611 |
| 2020's | 5 (6.49) | 2.80 |
| Authors | Studies |
|---|---|
| Kashiwagi, K | 1 |
| Ouchi, K | 1 |
| Shibasaki, Y | 2 |
| Suginaka, M | 1 |
| Lešták, J | 1 |
| Fůs, M | 1 |
| Weissová, I | 1 |
| Marešová, K | 1 |
| Harasymowycz, P | 1 |
| Royer, C | 1 |
| Cui, AX | 1 |
| Barbeau, M | 1 |
| Jobin-Gervais, K | 1 |
| Mathurin, K | 1 |
| Lachaine, J | 1 |
| Beauchemin, C | 1 |
| Lin, YH | 1 |
| Su, WW | 1 |
| Huang, SM | 1 |
| Chuang, LH | 1 |
| Chen, LC | 1 |
| Saito, Y | 1 |
| Kizaki, J | 1 |
| Wada, Y | 1 |
| Kishimoto, N | 1 |
| Aihara, M | 1 |
| Inoue, K | 1 |
| Shiokawa, M | 1 |
| Iwasa, M | 1 |
| Ishida, K | 1 |
| Tomita, G | 1 |
| Fuwa, M | 1 |
| Shimazaki, A | 1 |
| Mieda, M | 1 |
| Yamashita, N | 1 |
| Akaishi, T | 1 |
| Taniguchi, T | 1 |
| Kato, M | 1 |
| Chikama, T | 1 |
| Araie, M | 6 |
| Nishida, T | 1 |
| Yao, BQ | 1 |
| Pang, YY | 1 |
| Li, YX | 1 |
| Ali, J | 1 |
| Bhatnagar, A | 1 |
| Kumar, N | 1 |
| Ali, A | 1 |
| Yamamoto, T | 3 |
| Ikegami, T | 1 |
| Ishikawa, Y | 2 |
| Kikuchi, S | 1 |
| Sugiyama, T | 1 |
| Kojima, S | 1 |
| Ishida, O | 1 |
| Ikeda, T | 1 |
| Nakamoto, K | 1 |
| Yasuda, N | 1 |
| Kawai, K | 1 |
| Ohashi, H | 1 |
| Suzuki, T | 1 |
| Kitagaki, H | 1 |
| Fujisawa, S | 2 |
| Kawase, K | 1 |
| Muramatsu, T | 1 |
| Ono, J | 1 |
| Nakajima, T | 1 |
| Matsuhisa, A | 1 |
| Sugiura, T | 1 |
| Migita, M | 1 |
| Tokuda, N | 1 |
| Inoue, J | 1 |
| Yamazaki, I | 1 |
| Ueno, S | 1 |
| Kawai, M | 1 |
| Nagaoka, T | 1 |
| Takahashi, A | 1 |
| Sato, E | 1 |
| Yoshida, A | 1 |
| Ishii, Y | 1 |
| Nakamura, K | 1 |
| Matsuki, S | 1 |
| Uemura, N | 1 |
| Muraguchi, R | 1 |
| Nakagawa, M | 1 |
| Nakano, S | 1 |
| Nakatsuka, K | 1 |
| Blondin, C | 1 |
| Hamard, P | 1 |
| Cholley, B | 1 |
| Haeffner-Cavaillon, N | 1 |
| Baudouin, C | 3 |
| Ignat, F | 1 |
| Renard, P | 1 |
| Kovalski, JL | 1 |
| Cochereau, I | 1 |
| Jaulerry, S | 1 |
| Williamson, W | 1 |
| Elena, PP | 1 |
| Lablache Combier, M | 1 |
| Allaire, C | 2 |
| Siou-Mermet, R | 1 |
| Maruyama, K | 1 |
| Shirato, S | 2 |
| Malvitte, L | 1 |
| Montange, T | 1 |
| Vejux, A | 1 |
| Bron, AM | 1 |
| Creuzot-Garcher, C | 1 |
| Lizard, G | 1 |
| Ikeda, Y | 1 |
| Mori, K | 1 |
| Ishibashi, T | 1 |
| Naruse, S | 1 |
| Nakajima, N | 1 |
| Kinoshita, S | 1 |
| Negishi, C | 1 |
| Ueda, S | 1 |
| Kanai, A | 1 |
| Nakajima, A | 1 |
| Funahashi, M | 1 |
| Kitazawa, Y | 3 |
| Komemushi, S | 2 |
| Gorgone, G | 1 |
| Spina, F | 1 |
| Amantia, L | 1 |
| Fujio, N | 1 |
| Kitazawa, T | 1 |
| Azuma, I | 1 |
| Takase, M | 1 |
| Ishikawa, T | 1 |
| Okisaka, S | 1 |
| Hiwatari, S | 1 |
| Taketani, P | 1 |
| Sugimachi, Y | 1 |
| Tamaki, Y | 4 |
| Tomita, K | 3 |
| Tomidokoro, A | 4 |
| Nagahara, M | 3 |
| Zimmerman, TJ | 1 |
| Behrens-Baumann, W | 1 |
| Kimmich, F | 1 |
| Walt, JG | 1 |
| Lue, J | 1 |
| Yamazaki, S | 2 |
| Baba, H | 2 |
| Freedman, SF | 1 |
| Freedman, NJ | 1 |
| Shields, MB | 2 |
| Lobaugh, B | 1 |
| Samsa, GP | 1 |
| Keates, EU | 1 |
| Ollie, A | 1 |
| Marchal-Heussler, L | 1 |
| Sirbat, D | 1 |
| Hoffman, M | 1 |
| Maincent, P | 1 |
| Millar, JC | 1 |
| Wilson, WS | 1 |
| Carr, RD | 1 |
| Humphries, RG | 1 |
| Maeda, H | 1 |
| Tanaka, Y | 1 |
| Yamamoto, M | 1 |
| Mizokami, K | 1 |
| Koseki, N | 1 |
| Yamagami, J | 1 |
| Stewart, WC | 2 |
| Cohen, JS | 2 |
| Netland, PA | 1 |
| Weiss, H | 1 |
| Nussbaum, LL | 1 |
| de Lunardo, C | 1 |
| Camerino, L | 1 |
| Gastaldi, C | 1 |
| Brogliatti, B | 1 |
| Boles Carenini, B | 1 |
| Muta, K | 1 |
| Bartlett, JD | 1 |
| Olivier, M | 1 |
| Richardson, T | 1 |
| Whitaker, R | 1 |
| Pensyl, D | 1 |
| Wilson, MR | 1 |
| Mirza, GE | 1 |
| Karaküçük, S | 1 |
| Temel, E | 1 |
| Kasper, J | 1 |
| Champion, C | 1 |
| Flammer, J | 1 |
| Haefliger, IO | 1 |
| Séchoy, O | 1 |
| Tissié, G | 1 |
| Sébastian, C | 1 |
| Maurin, F | 1 |
| Driot, JY | 1 |
| Trinquand, C | 2 |
| Demailly, P | 1 |
| Watson, PG | 1 |
| Barnett, MF | 1 |
| Parker, V | 1 |
| Haybittle, J | 1 |
| Dahlmann, AH | 1 |
| Benson, MT | 1 |
| Sato, T | 1 |
| Muto, T | 1 |
| Ishibashi, Y | 1 |
| Roy, S | 1 |
| Vercruysse, K | 1 |
| Goethals, M | 1 |
| Vandeputte, O | 1 |
| Missotten, L | 1 |
| Kato, Y | 1 |
| Sasaki, T | 1 |
| Tsukahara, S | 1 |
| Weber, U | 2 |
| Bähr, C | 1 |
| Michaelis, L | 2 |
| Mayer, H | 1 |
| Wirth, K | 1 |
| Tokoro, T | 1 |
| Grunwald, JE | 1 |
| Delehanty, J | 1 |
| Takayanagi, I | 1 |
| Hagiwara, H | 1 |
| Koike, K | 1 |
| Hosokawa, T | 1 |
| Kasuya, Y | 1 |
| Allen, RC | 1 |
| Lewis, RA | 1 |
| Hoskins, HD | 1 |
| Hetherington, JN | 1 |
| Bahr, RL | 1 |
| Noblin, JE | 1 |
| Delehanty, JT | 1 |
| Hirota, A | 1 |
| Mishima, H | 1 |
| Kiuchi, Y | 1 |
| Nagata, A | 1 |
| Kurokawa, T | 1 |
| Ishibashi, S | 1 |
| Collignon-Brach, J | 1 |
| James, IM | 1 |
| Pillunat, LE | 1 |
| Stodtmeister, R | 2 |
| Pillunat, L | 1 |
| Wilmanns, I | 1 |
| Neubrand, M | 1 |
| Finger, B | 1 |
| Tobias, G | 1 |
| Sugiyama, K | 1 |
| Enya, T | 1 |
| Ohno, S | 1 |
| Ichiishi, A | 1 |
| Matsuda, H | 1 |
| Berlin, I | 1 |
| Marcel, P | 1 |
| Uzzan, B | 1 |
| Millon, D | 1 |
| Le Hoang, P | 1 |
| Puech, AJ | 1 |
| Schnarr, KD | 1 |
| Duff, GR | 2 |
| Newcombe, RG | 1 |
| Scoville, B | 1 |
| Mueller, B | 1 |
| White, BG | 1 |
| Krieglstein, GK | 1 |
| Brazier, DJ | 1 |
| Smith, SE | 1 |
| Schnaudigel, OE | 1 |
| Becker, H | 1 |
| Fuchs, HB | 1 |
| van Husen, H | 1 |
| Flury, H | 1 |
| Tournoux, A | 1 |
| Martenet, AC | 1 |
3 reviews available for carteolol and Intraocular Pressure
| Article | Year |
|---|---|
Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
Topics: Amides; Antihypertensive Agents; Bayes Theorem; Betaxolol; Bimatoprost; Brimonidine Tartrate; Carteo | 2022 |
Topical ophthalmic beta blockers: a comparative review.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Carteolol; Drug Tolerance; | 1993 |
Pharmacologic effects of beta-blocking agents used in the management of glaucoma.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Heart Rate; Humans; Intraocular Pressur | 1989 |
40 trials available for carteolol and Intraocular Pressure
| Article | Year |
|---|---|
Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study.
Topics: Antihypertensive Agents; Carteolol; Cross-Over Studies; Drug Combinations; Glaucoma, Open-Angle; Hum | 2021 |
[Influence on ocular surface and intraocular pressure of switching from preservative-containing to preservative-free carteolol hydrochloride ophthalmic solution].
Topics: Aged; Aged, 80 and over; Carteolol; Corneal Diseases; Female; Glaucoma; Humans; Intraocular Pressure | 2013 |
[Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma].
Topics: Aged; Aged, 80 and over; Carteolol; Cloprostenol; Female; Glaucoma, Angle-Closure; Humans; Intraocul | 2013 |
Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Carteolol; Dos | 2016 |
Changes in optic nerve head blood flow induced by the combined therapy of latanoprost and beta blockers.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Blood Flow Velocity; Blood Pressu | 2009 |
[Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intrao | 2010 |
Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity.
Topics: Administration, Intranasal; Administration, Topical; Adrenergic beta-Antagonists; Adult; Area Under | 2002 |
Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carteolol; Cross-Over Studies; Delayed-Action | 2005 |
Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
Topics: Antihypertensive Agents; Carbonic Anhydrase Inhibitors; Carteolol; Cross-Over Studies; Drug Synergis | 2006 |
[Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
Topics: Adrenergic beta-Antagonists; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; | 2007 |
Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Carteolol; Female; Glaucoma, Open-A | 2008 |
[Effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Carteolol; Clinical Trials as Topic; Dose-Response Relationship, | 1981 |
Carteolol: preliminary study on ocular pressure-reducing action.
Topics: Adult; Aged; Carteolol; Clinical Trials as Topic; Female; Glaucoma, Open-Angle; Humans; Intraocular | 1983 |
[Ocular hypotensive effects of carteolol hydrochloride in primary open-angle glaucoma and ocular hypertensive patients. A double-masked cross-over study for the determination of concentrations optimal for the clinical use (author's transl)].
Topics: Carteolol; Clinical Trials as Topic; Double-Blind Method; Glaucoma, Open-Angle; Humans; Intraocular | 1981 |
A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Carteolol; Child; Double-Blind | 1994 |
Acute effect of topical carteolol on ocular pulsatile volume change.
Topics: Administration, Topical; Adult; Blood Flow Velocity; Carteolol; Eye; Female; Heart Rate; Humans; Int | 1993 |
Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level.
Topics: Administration, Topical; Adult; Carteolol; Cholesterol; Cholesterol, HDL; Double-Blind Method; Eye; | 1993 |
[Effect of non-surgical ocular hypotensive therapy in normal-tension glaucoma].
Topics: Carteolol; Drug Therapy, Combination; Epinephrine; Glaucoma; Humans; Intraocular Pressure; Middle Ag | 1997 |
Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carteolol; Double-Blind Met | 1997 |
Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers.
Topics: Administration, Topical; Adolescent; Adrenergic beta-Antagonists; Adult; Benzalkonium Compounds; Car | 1998 |
Effects of topical adrenergic agents on tissue circulation in rabbit and human optic nerve head evaluated with laser speckle tissue circulation analyzer.
Topics: Administration, Topical; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Animals; | 1997 |
Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women.
Topics: Adrenergic beta-Antagonists; Aged; Black People; Brain; Carteolol; Double-Blind Method; Female; Glau | 1999 |
Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intraocul | 2000 |
Ocular hypotensive efficacy and safety of once daily carteolol alginate.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Alginates; Analysis of Vari | 2001 |
A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Carteolol; Drug Therapy, Combination; Female; Glaucoma | 2001 |
A long term clinical trial of carteolol in the management of glaucoma. Belgian Carteolol Study Participants.
Topics: Adult; Aged; Carteolol; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Visual Fi | 1992 |
[Effect of 8-hydroxycarteolol in normal human eyes].
Topics: Adrenergic beta-Antagonists; Adult; Carteolol; Depression, Chemical; Double-Blind Method; Eye; Femal | 1992 |
Carteolol incorporated into FAT-MLV liposomes: prolonged and decreased reduction of IOP.
Topics: Carteolol; Cataract Extraction; Double-Blind Method; Drug Carriers; Humans; Intraocular Pressure; Le | 1992 |
[The effect of carteolol. Prolonged and increased effect by liposome suspension].
Topics: Animals; Carteolol; Cataract Extraction; Drug Carriers; Humans; Intraocular Pressure; Lenses, Intrao | 1992 |
Effect of topical carteolol on the normal human retinal circulation.
Topics: Administration, Topical; Adult; Blood Flow Velocity; Carteolol; Double-Blind Method; Fundus Oculi; H | 1992 |
A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Blood Pressure; Carteolol; Dosage Forms; Do | 1991 |
Early visual field changes with beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carteolol; Drug Evaluation, Preclinical; Follow-Up Studies; | 1989 |
[Effect of carteolol and timolol eyedrops on the pressure tolerance of the optic nerve head].
Topics: Adaptation, Physiological; Adult; Carteolol; Double-Blind Method; Female; Humans; Intraocular Pressu | 1989 |
A single dose of three different ophthalmic beta-blockers antagonizes the chronotropic effect of isoproterenol in healthy volunteers.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carteolol; Double-Blind Method; Heart Rate; Huma | 1987 |
The 12-hour control of intraocular pressure on carteolol 2% twice daily.
Topics: Aged; Aged, 80 and over; Carteolol; Clinical Trials as Topic; Double-Blind Method; Female; Glaucoma; | 1988 |
A double-masked comparison of carteolol and timolol in ocular hypertension.
Topics: Administration, Topical; Ambulatory Care; Carteolol; Clinical Trials as Topic; Drug Administration S | 1988 |
A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure.
Topics: Carteolol; Clinical Trials as Topic; Humans; Intraocular Pressure; Ocular Hypertension; Propanolamin | 1987 |
Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers.
Topics: Adult; Blood Pressure; Cardiovascular System; Carteolol; Depression, Chemical; Double-Blind Method; | 1988 |
[1% carteolol hydrochloride eyedrops: long-term experience in the treatment of chronic open-angle glaucoma].
Topics: Carteolol; Clinical Trials as Topic; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pr | 1986 |
[Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops].
Topics: Adult; Aged; Carteolol; Double-Blind Method; Female; Glaucoma; Glaucoma, Open-Angle; Heart Rate; Hum | 1986 |
34 other studies available for carteolol and Intraocular Pressure
| Article | Year |
|---|---|
Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions.
Topics: Antihypertensive Agents; Carteolol; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Ocular Hype | 2023 |
Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma.
Topics: Betaxolol; Carteolol; Evoked Potentials, Visual; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular | 2020 |
Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide.
Topics: Angiography; Brimonidine Tartrate; Carteolol; Female; Fluorescein Angiography; Glaucoma; Glaucoma, O | 2021 |
Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Carteolol; Drug Combinations; Drug Substitu | 2018 |
Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol.
Topics: Animals; Antihypertensive Agents; Carteolol; Cell Line; Drug Combinations; Epithelium, Corneal; Huma | 2019 |
Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits.
Topics: Adhesiveness; Animals; Carteolol; Chitosan; Cornea; Drug Carriers; Glaucoma; Hydroquinones; Intraocu | 2014 |
Effect of carteolol hydrochloride on 24-hour variation of intraocular pressure in normal-tension glaucoma.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carteolol; Circadian Rhythm; Female; Heart Rate; Humans | 2010 |
[Effect of anti-glaucoma drugs on inflammatory cytokine production by human and murine peripheral blood mononuclear cells].
Topics: Adrenergic beta-Antagonists; Adult; Animals; Carteolol; Cells, Cultured; Enzyme-Linked Immunosorbent | 2010 |
Effects of a long-acting ophthalmic formulation of carteolol containing alginic acid on the corneal epithelial barrier function and water retentive effect.
Topics: Adult; Alginates; Antihypertensive Agents; Carteolol; Cross-Over Studies; Delayed-Action Preparation | 2012 |
Effects of topical carteolol on retinal arterial blood flow in primary open-angle glaucoma patients.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Fl | 2012 |
In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system.
Topics: Adrenergic beta-Antagonists; Benzalkonium Compounds; Betaxolol; Carteolol; Complement System Protein | 2003 |
[Neuroprotection and vasoprotection in glaucoma].
Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Carteolol; Drug Therapy, Combination; Glau | 2004 |
Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs.
Topics: Administration, Topical; Aged; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; C | 2007 |
[Intraocular penetration of 14C-Carteolol hydrochloride (beta-blocker) in the albino rabbits].
Topics: Animals; Aqueous Humor; Carbon Radioisotopes; Carteolol; Dose-Response Relationship, Drug; Eye; Intr | 1984 |
[Pilocarpine, carbachol and carteolol on open-angle glaucoma and ocular hypertension (author's transl)].
Topics: Adolescent; Adult; Aged; Carbachol; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intraocular Pre | 1981 |
[Effect of topical carteolol on tissue circulation in rabbit optic nerve head evaluated with the laser speckle microcirculation analyser].
Topics: Administration, Topical; Animals; Carteolol; Instillation, Drug; Intraocular Pressure; Lasers; Optic | 1995 |
Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery.
Topics: Animals; Blood Pressure; Capsules; Carteolol; Chemical Phenomena; Chemistry, Physical; Heart Rate; H | 1993 |
Drug effects on intraocular pressure and vascular flow in the bovine perfused eye using radiolabelled microspheres.
Topics: Adrenergic beta-Antagonists; Animals; Blood Flow Velocity; Carteolol; Cattle; Cerium Radioisotopes; | 1995 |
[Effect of topical carteolol on visual function in normal-tension glaucoma].
Topics: Administration, Topical; Carteolol; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Middle Aged; | 1997 |
Effect of topical beta-blockers on tissue blood flow in the human optic nerve head.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Blood Flow Velocity; Blood Pressure; Ca | 1997 |
Conjunctival vs sublingual administration of carteolol 2% eye drops. Ocular hypotensive effects and some systemic parameter changes.
Topics: Administration, Sublingual; Adrenergic beta-Antagonists; Aged; Carteolol; Chronic Disease; Conjuncti | 1997 |
Effects of topical carteolol and timolol on tissue circulation in the iris and choroid.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Blood Circulation; Blood Flow Velocit | 1999 |
Vasorelaxing properties of carteolol in isolated porcine ciliary arteries.
Topics: Adrenergic beta-Antagonists; Animals; Carteolol; Ciliary Arteries; Endothelium, Vascular; In Vitro T | 2000 |
A new long acting ophthalmic formulation of carteolol containing alginic acid.
Topics: Adhesiveness; Alginates; Animals; Antihypertensive Agents; Biological Availability; Carteolol; Diffu | 2000 |
Spontaneous hyphema secondary to iris vascular tufts.
Topics: Aged; Anti-Inflammatory Agents; Atropine; Betamethasone; Carteolol; Drug Therapy, Combination; Human | 2001 |
Short-term effect of beta-adrenoreceptor blocking agents on ocular blood flow.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Blood Flow Velocity; Blood | 2001 |
[Effects of timolol and carteolol on ocular pulsatile blood flow].
Topics: Adult; Carteolol; Eye; Humans; Intraocular Pressure; Pulsatile Flow; Regional Blood Flow; Timolol | 1992 |
Effects of the R(+)- and S(-)-isomers of beta-adrenoceptor blockers with intrinsic sympathomimetic activity, befunolol and carteolol, on rabbit intraocular pressure.
Topics: Adrenergic beta-Antagonists; Animals; Carteolol; Intraocular Pressure; Male; Ophthalmic Solutions; P | 1991 |
[Effect of topical 8-hydroxy carteolol on intraocular pressure and melanin granules].
Topics: Administration, Topical; Animals; Carteolol; Female; Intraocular Pressure; Male; Melanins; Ophthalmi | 1991 |
Pressure compliance test of the optic nerve head: influence of different antiglaucoma drugs.
Topics: Acetazolamide; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Glaucoma, Open-Angle; Hu | 1989 |
Ocular hypotensive effect of 8-hydroxycarteolol, a metabolite of carteolol.
Topics: Administration, Topical; Animals; Carteolol; Double-Blind Method; Intraocular Pressure; Macaca fasci | 1989 |
Hypotensive effect of carteolol on intraocular pressure elevation and secondary glaucoma associated with endogenous uveitis.
Topics: Adolescent; Adult; Aged; Blood Pressure; Carteolol; Child; Drug Administration Schedule; Female; Gla | 1989 |
[Comparative multicenter study of carteolol eyedrops with other beta blockers in 768 patients under normal conditions].
Topics: Adrenergic beta-Antagonists; Carteolol; Drug Evaluation; Glaucoma; Humans; Intraocular Pressure; Met | 1988 |
[Carteolol: general practice-oriented assessment of the effectiveness and tolerance of a new beta-blocker in the treatment of glaucoma].
Topics: Carteolol; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Propanolamines | 1988 |